Want to see FR:ALIMP full AI Analyst Report?
ALIMP Stock Chart & Stats
€0.26
<€0.01(1.57%)
At close: 4:00 PM EST
€0.26
<€0.01(1.57%)
Day’s Range― - ―
52-Week Range€0.15 - €0.44
Previous CloseN/A
Volume2.90K
Average Volume (3M)332.66K
Market Cap
€23.21M
Enterprise Value€28.91
Total Cash (Recent Filing)€3.01M
Total Debt (Recent Filing)€5.92M
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Sep 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding143,818,970
10 Day Avg. Volume485,065
30 Day Avg. Volume332,657
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)70.59
Price to Sales (P/S)2.29
P/FCF Ratio-13.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Top-line ReboundSustained revenue growth over multiple years signals rising market adoption of Implanet’s implants and systems. A growing top line can drive operating leverage, support larger R&D and commercial investments, and provide a firmer base to pursue profitability if the growth trajectory persists.
Improving Gross MarginsA material margin expansion suggests improving product mix, pricing power, or cost efficiencies in production and distribution. Higher gross margins improve the company’s structural ability to absorb SG&A and R&D, shortening the path from revenue growth to sustainable operating profitability.
Recurring Implant/consumable ModelImplant platforms with recurring consumable and follow-on component purchases create sticky, repeat revenue streams. This structural aftermarket exposure can support predictable unit demand per procedure and higher lifetime customer value as hospital and surgeon adoption deepens.
Bears Say
Persistent LossesContinued material net losses constrain internal funding for growth and force reliance on funding rounds or debt. Ongoing unprofitability limits free cash generation and reduces flexibility to invest in commercialization or product development without diluting or levering the balance sheet.
High Leverage, Thin EquityA structurally weak capital structure—with high debt relative to vanishing equity—elevates refinancing and solvency risk. Limited equity cushion amplifies downside from operational volatility, increases interest burden, and may restrict access to favorable financing when losses persist.
Negative Operating & Free Cash FlowAlthough operating cash flow has improved, persistent negative OCF and FCF mean the company remains dependent on external funding for working capital and capex. This structural cash shortfall limits reinvestment capacity and raises execution risk until sustained positive cash generation is achieved.
ALIMP FAQ
What was Implanet SA’s price range in the past 12 months?
Implanet SA lowest stock price was €0.15 and its highest was €0.44 in the past 12 months.
What is Implanet SA’s market cap?
Implanet SA’s market cap is €23.21M.
When is Implanet SA’s upcoming earnings report date?
Implanet SA’s upcoming earnings report date is Sep 15, 2026 which is in 39 days.
How were Implanet SA’s earnings last quarter?
Implanet SA released its earnings results on Feb 24, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Implanet SA overvalued?
According to Wall Street analysts Implanet SA’s price is currently Overvalued.
Does Implanet SA pay dividends?
Implanet SA does not currently pay dividends.
What is Implanet SA’s EPS estimate?
Implanet SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Implanet SA have?
Implanet SA has 143,818,970 shares outstanding.
What happened to Implanet SA’s price movement after its last earnings report?
Implanet SA reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 16.162%.
Which hedge fund is a major shareholder of Implanet SA?
Currently, no hedge funds are holding shares in FR:ALIMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Implanet SA
Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. Its spinal offerings encompass various posterior fixation systems, including the Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw lines. Furthermore, Implanet S.A. provides knee prostheses, which are marketed under the Madison brand. The company has a significant strategic alliance with Shanghai Sanyou Medical Co, Ltd. Established in 2006, Implanet S.A. operates from its headquarters in Martillac, France.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Theraclion SA
―
Diagnostic Medical Systems
―
Median Technologies
―
Affluent Medical SA
―